Gemcitabine, Nab-paclitaxel Plus the TheraBionic P1 (an Amplitude-Modulated Radiofrequency Electromagnetic Fields) Device to Treat Metastatic Pancreatic Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Anthony F Shields, M.D. PhD
Barbara Ann Karmanos Cancer Institute
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Karmanos Cancer Institute at Mclaren Clarkston
Clarkston, Michigan, United States
Recruiting - Karmanos Cancer Institute
Detroit, Michigan, United States
Anthony F Shields, M.D. PhDMohammed N Al Hallak, M.D.Wasif Saif, M.D.Recruiting - Karmanos Cancer Institute at Mclaren Flint
Flint, Michigan, United States
Recruiting - Karmanos Cancer Institute at Mclaren Greater Lansing
Lansing, Michigan, United States
Recruiting - Karmanos Cancer Institute at Mclaren Lapeer Region
Lapeer, Michigan, United States
Recruiting - Karmanos Cancer Institute at Mclaren Northern Michigan, Petoskey
Petoskey, Michigan, United States
Recruiting - Karmanos Cancer Institute at Mclaren Port Huron
Port Huron, Michigan, United States
Recruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 28 Feb 2025
- Primary completion
- 31 Jul 2027
- Completion
- 31 Jul 2027
- Last update posted
- 5 Nov 2025
- Registered enrollment
- 30
- Registry id
- NCT06576115
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.